

Additional information provided by New Zealand:

Below are example applications made to the New Zealand Environmental Protection Authority highlighting various aspects of socio-economic considerations consistent with our domestic legislation (the Hazardous Substances and New Organisms Act) and Article 26 of the Cartagena Protocol:

- o GM Importation into containment: [APP202934](#) – Sample 6, a GMO listeria detection system for use in the food industry
- o GM Development: [APP203059](#) – to Callaghan Innovation and the University of Canterbury for the genetic modification and large-scale fermentation of various microorganisms, mammalian cell lines, and primary cell cultures.
- o GM Field testing: [ERMA200479](#) – to Scion (the NZ Forest Research Institute) for the field trial of GM radiata pine
- o GM Release: [APP202371](#) – to Sanofi Aventis, for the use of IMOJEV, a GM chimaeric live-attenuated virus for the vaccination of travellers against Japanese encephalitis virus

It is our view that the former two applications effectively highlight economic benefit to food producers and health benefit to New Zealand consumers (APP202934), as well as for the potential to benefit businesses, including Māori businesses, in the future (APP203059). We view the latter two applications as effectively highlighting engagement with and realising benefit to mana whenua hapū in addition to potential general economic benefits (ERMA200479), as well as assessment of a number of criteria of importance to Māori in the use of a medicine in addition to general human health benefits (APP202371).